Thyroid cancer, RET-positive
Revision as of 23:58, 28 August 2020 by Jwarner (talk | contribs) (Created page with "Note: these are regimens tested in biomarker-specific populations, please see the '''main thyroid cancer page''' for other regimens. {| class="wikitable" st...")
Note: these are regimens tested in biomarker-specific populations, please see the main thyroid cancer page for other regimens.
2 regimens on this page
2 variants on this page
|
Advanced or metastatic disease
Selpercatinib monotherapy
| back to top |
Regimen
| FDA-recommended dose |
| Study | Evidence |
|---|---|
| Wirth et al. 2020 (LIBRETTO-001) | Phase I/II (RT) |
Biomarker eligibility criteria
- RET fusion-positive thyroid cancer
- RET-mutant medullary thyroid cancer
Chemotherapy
- Selpercatinib (Retevmo) with or without food, as follows:
- Less than 50 kg: 120 mg PO twice per day
- 50 kg or more: 160 mg PO twice per day
Continued indefinitely
References
- LIBRETTO-001: Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27;383(9):825-835. link to original article PubMed NCT03157128